Vimarsana
Biggest News Aggregation in the World

Accine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accine . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accine Today - Breaking & Trending Today

Odisha's First Vaccine Manufacturing Plant to Start Production by May - Vimarsana News

Odisha's First Vaccine Manufacturing Plant to Start Production by May

The plant at the Biotech Park in Andharua will have the capacity to produce 2.4 crore doses of different vaccines per day. It is expected to produce over 15 vaccines for various diseases, including cholera and malaria

Source: news18.com
November drive targets polio-free future - Vimarsana News

November drive targets polio-free future

Emphasis on polio eradication, declared national emergency in the country, remains the government’s top priority

New COVID-19 vaccine successfully tested - Vimarsana News

New COVID-19 vaccine successfully tested

Rocketvax and Basel University therapy uses a modified coronavirus that activates an immune response - News - PharmaTimes

MyJournals.org - Science - 'Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India' (Drug Safety) - Vimarsana News

MyJournals.org - Science - 'Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India' (Drug Safety)

MyJournals.org - Science - 'Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India' (Drug Safety)

First patient dosed in pivotal CureVac flu vaccine study - Vimarsana News

First patient dosed in pivotal CureVac flu vaccine study

Modified influenza vaccine candidates have been developed in collaboration with GSK - News - PharmaTimes